Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Astellas Launches XOSPATA for Relapsed/Refractory AML with a FLT3 Mutation

americanpharmaceuticalreviewDecember 12, 2018

Tag: Astellas , Xospata , FLT3 Mutation , AML

PharmaSources Customer Service